NA - Biomarker validation hypothesis · neurodegeneration · -
Composite 0.595
Price $0.51
Evidence For 0
Evidence Against 0
Amyloid PET normalizes faster than CSF p-tau217 due to differential compartment kinetics (vascular vs. neuronal). Using amyloid PET alone for stopping may prematurely halt treatment before downstream tau pathology resolution. This hypothesis remains biologically plausible but lacks outcome validation—the clinical inference (dual threshold required) is not yet supported by data showing harm from amyloid-PET-only stopping.
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.70
Evidence
0.58
Novelty
0.65
Feasibility
0.60
Impact
0.68
Druggability
0.20
Safety
0.55
Competition
0.75
Data
0.65
Reproducible
0.60
KG Connect
0.50
Score Breakdown
Dimension
Temporal Decoupling of CSF p-t
Mechanistic
0.700
Evidence
0.580
Novelty
0.650
Feasibility
0.600
Impact
0.680
Druggability
0.200
Safety
0.550
Competition
0.750
Data
0.650
Reproducible
0.600
KG Connect
0.500
Evidence
Temporal Decoupling of CSF p-tau217 Normalization from Amylo